IRIG yields 4000.00% · ABBV yields 3.06%● Live data
📍 IRIG pulled ahead of the other in Year 1
Combined, IRIG + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IRIG + ABBV for your $10,000?
Integrated Drilling Equipment Holdings Corp. manufactures drilling rigs, rig control systems, and rig components; and provides rig refurbishment and reconfiguration services for contract drilling companies worldwide. It operates through two segments, Electrical Products and Services, and Drilling Products and Services. The Electrical Products and Services segment designs, manufactures, installs, and services rig electrical and control systems, such as silicon controlled rectifier units, variable frequency drive units, electrical cabling, lighting systems, closed circuit video systems, gas and fire detection systems, and communication systems. This segment also offers rig power systems, AC and DC drive systems and MCC, electrical rig up, engine generators, automation, controls/sensors, hydraulic power units, other rig related hydraulic solutions, system integration, hydraulic system design, testing, and rig up/support products and services. The Drilling Products and Services segment provides drilling rigs and components. This segment designs, manufactures, and services land-based drilling rigs, and rig subsystems and parts; offers drilling rig services comprising mechanical services, assembly testing, rig refurbishment and inspection, new rig fabrication, and completion of land rig packages; and fabricates mud tanks, masts and substructures, dog houses, and other drilling rig related products. Integrated Drilling Equipment Holdings Corp. is headquartered in Spring, Texas.
Full IRIG Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.